35,000
people die of chronic or cirrhotic liver diseases each year in US
13,705
patients were on the waiting list for a liver transplantation in the US in 2016
7,841
liver transplants were reported in the US in 2016

Promethera® Biosciences aims to bring patients life-saving treatments to reduce the need for liver transplantation.

Our passion translates into a commitment to holistically change patients’ lives by not only developing pioneering liver therapies, but also providing high quality education about liver disease and how to prevent it through healthy lifestyle choices.

We are developing cutting-edge cell- and antibody-based therapies for the treatment of liver diseases.

HepaStem is our most advanced cell-based therapy which has the potential to deliver novel treatment options for chronic and acute liver diseases including Acute-on-Chronic Liver Failure (ACLF), fibrosis and Non-Alcoholic SteatoHepatitis (NASH).

A unique set of technological assets, exclusive IP & know-how.

A broad intellectual property portfolio, which includes a proprietary antibody therapy, human organ and cell sourcing and manufacturing capabilities, positions the Promethera® Group as a global leader in regenerative medicine and cell therapy for liver diseases.

Restoring Liver Health

Twitter feed

Our website was updated to promote our new brand identity and strong #patient focus. We look forward to serving patients with liver diseases such as #NASH and #ACLF in the coming years. See our updated website at

Our new website now uses an international structure as we operate in 4 countries. We look forward to expanding our global presence and helping patients around the world. Explore the new website at

Excited to launch Promethera's new branding and website! This brand relaunch captures our productive transformation and growth over the past decade. Check out the new website at